Enlivex Ltd. (ENLV)
NASDAQ
$0.5975−$0.0082 (−1.35%) on the dayAs of the close; data may be delayed.
ENLV price, last 12 months
Key stats
- Previous close
- $0.6057
- Open
- $0.6000
- Day range
- $0.5800 – $0.6200
- 52-week range
- $0.5700 – $27.15
- Volume
- 317.5K
- Avg volume (20 days)
- 416.4K
- Market cap
- $10.4M
Performance
1W−25.9%
1M−60.6%
3M−93.0%
6M−96.4%
YTD−94.3%
1Y−96.2%
vs S&P 500, 1Y−113.0 pts
Technicals and fundamentals
About Enlivex Ltd.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.
- Listed on
- NASDAQ
- Market cap
- $10.4M